Andere Sprachen Hepion Pharmaceuticals, Inc.

Aktien

A3EEV3

US4268973025

HEPA

Verzögert Nasdaq Andere Börsenplätze 15:45:35 18.06.2024			% 5 Tage	% 1. Jan.
1,085 ^USD	+5,34 %		-6,36 %	-68,21 %

21.05.	Hepion Pharmaceuticals, Inc. meldet Ergebnis für das erste Quartal bis zum 31. März 2024	CI
19.04.	Hepion Pharmaceuticals, Inc. beginnt mit dem Abbau der Aktivitäten in der Phase-2b-Studie ASCEND-NASH Studie	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Hepion Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	21.05.
Sector Update: Health Care Stocks Increase Late Afternoon	22.04.
Sector Update: Health Care	22.04.
Top Midday Decliners	22.04.
Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b 'ASCEND-NASH' Trial	22.04.
North American Morning Briefing: Stock Futures Rise, Busy Week of Earnings Ahead	22.04.
Hepion Pharmaceuticals Starts Wind-Down Activities in Phase 2b ASCEND-NASH Trial	19.04.
Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ Trial	19.04.
Hepion Pharmaceuticals, Inc. Initiates Wind-Down Activities in Phase 2b ?ASCEND-NASH? Trial	19.04.
Hepion Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	16.04.
Hepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael Purcell	06.03.
Hepion Pharmaceuticals, Inc. Appoints Michael Purcell to Its Board of Directors	06.03.
Hepion Pharmaceuticals, Inc. Announces Board Changes	20.02.
Hepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross Proceeds	16.02.
Hepion Pharmaceuticals, Inc. Announces Resignation of Anand Reddi from the Board of Directors	07.02.
Hepion Pharmaceuticals to Present at NASH-TAG 2024	03.01.
North American Morning Briefing : Futures Pause -2-	08.12.
Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value	07.12.
Hepion Pharmaceuticals Approves Restructuring Plan to Preserve Capital, Launches Strategic Review Process	07.12.
Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management Changes	07.12.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Hepion Pharmaceuticals, Inc.

Aktien

A3EEV3

US4268973025

HEPA

Andere Sprachen

Filter